Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Significant Event: Submission of an Initial Director's Interest Notice for a director named Cunningham (Exhibit 99.1).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate governance disclosures rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary change noted is the filing of a Director's Interest Notice.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate the Director's Interest Notice into existing Registration Statements (Form S-8 and Form F-3).
Key Facts for Investor Verification
- Verify the specific nature and extent of the interest declared by Director Cunningham in Exhibit 99.1.
- Confirm the status of the company's ongoing development stage operations, as no financial results are reported here.
- Review the referenced Registration Statements (S-8 and F-3) for broader context on capital structure and equity offerings.